Candel Therapeutics (CADL) Total Current Liabilities: 2020-2023

Historic Total Current Liabilities for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $10.3 million.

  • Candel Therapeutics' Total Current Liabilities rose 75.09% to $10.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.3 million, marking a year-over-year increase of 75.09%. This contributed to the annual value of $5.6 million for FY2022, which is 4.72% up from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Total Current Liabilities is $10.3 million, which was up 26.51% from $8.2 million recorded in Q2 2023.
  • Candel Therapeutics' 5-year Total Current Liabilities high stood at $10.3 million for Q3 2023, and its period low was $4.4 million during Q3 2021.
  • Its 3-year average for Total Current Liabilities is $6.1 million, with a median of $5.5 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Candel Therapeutics' Total Current Liabilities was 75.09% (2023), while the steepest drop was 4.31% (2023).
  • Quarterly analysis of 4 years shows Candel Therapeutics' Total Current Liabilities stood at $4.7 million in 2020, then rose by 13.77% to $5.4 million in 2021, then rose by 4.72% to $5.6 million in 2022, then spiked by 75.09% to $10.3 million in 2023.
  • Its Total Current Liabilities stands at $10.3 million for Q3 2023, versus $8.2 million for Q2 2023 and $5.2 million for Q1 2023.